<DOC>
	<DOCNO>NCT00003924</DOCNO>
	<brief_summary>RATIONALE : Interferon-alfa may interfere growth cancer cell . Giving interferon-alfa follow chemotherapy peripheral stem cell transplantation may effective treatment Hodgkin 's disease non-Hodgkin 's lymphoma . PURPOSE : Randomized phase III trial determine effectiveness interferon alfa-2b follow chemotherapy stem cell transplantation treat patient recurrent refractory Hodgkin 's disease non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Interferon Alfa-2b Following Chemotherapy Peripheral Stem Cell Transplantation Treating Patients With Recurrent Refractory Hodgkin 's Disease Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine efficacy interferon alfa-2b reduce relapse rate patient recurrent refractory Hodgkin 's disease non-Hodgkin 's lymphoma second remission follow high dose chemotherapy autologous stem cell transplantation . II . Compare time disease progression survival patient population treat interferon alfa-2b v treatment . III . Assess tolerability treatment regimens patient . OUTLINE : This randomize , multicenter study . Patients stratify accord lymphoma subtype . Patients randomize one two treatment arm . Arm I : Patients receive therapy follow high dose chemotherapy autologous stem cell transplantation . Arm II : Beginning 4 week high dose chemotherapy autologous stem cell transplantation , patient receive interferon alfa-2b subcutaneously three time week . Treatment continue 18 month absence disease progression unacceptable toxicity . Patients follow every 6 month disease progression . PROJECTED ACCRUAL : A total 360 patient ( 180 per treatment arm ) accrue study within 4-5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove nonHodgkin 's lymphoma Hodgkin 's disease Diffuse small cell ( i.e. , chronic lymphocytic leukemia , small lymphocytic , immunocytoma ) Follicular Mantle cell Peripheral T cell Diffuse large B cell Leukemic ( i.e. , lymphoblastic , Burkitt 's ) First relapse first progression respond salvage regimen high dose chemotherapy autologous stem cell transplantation ( second remission ) Response great 50 % tumor mass decrease observe time progression Prior high dose chemotherapy plus autologous stem cell transplantation first line therapy allow PATIENT CHARACTERISTICS : Age : 18 64 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 1.5 mg/dL Transaminase great 3.0 time upper limit normal Renal : Creatinine great 1.7 mg/dL Other : Not pregnant nursing Fertile patient must use effective contraception No prior concurrent malignancy except curatively treat ( radiotherapy surgery ) basal cell skin cancer carcinoma situ PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics No concurrent immunotherapy No concurrent hematopoietic growth factor Chemotherapy : See Disease Characteristics No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : No concurrent radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>Waldenstr√∂m macroglobulinemia</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>